UBI集團訊息

View More
UBI集團訊息
25032020
聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗

中國國家藥品監督管理局(National Medical Products Administration，NMPA)已核准其開發中抗體新藥UB-221之I 期臨床試驗的申請

UBI group

創新型IgE單株抗體UB-221
more
聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗
View More
UBI集團訊息
22032020
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients

They have received Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to evaluate UB-421’s efficacy

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
View More
UBI集團訊息
22032020
中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請

中國國家藥品監督管理局(NMPA)核准其治療HIV-1感染抗體新藥UB-421之II 期功能性治癒概念驗證臨床試驗的申請

UBI group

愛滋病治療單株抗體UB-421
more
中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請
View More
UBI集團訊息
22032020
檢測試劑來了！美FDA授權開賣

聯亞生技集團（UBI）旗下聯合生物製藥（聯生藥）展現研發能量，已開發出新冠病毒抗體血液檢測試劑

UBI group
more
檢測試劑來了！美FDA授權開賣
View More
UBI集團訊息
22032020
聯亞生技四路並進攻堅新冠肺炎病毒帶來的災難

聯亞生技集團於3月19日受新竹科學園區管理局之邀請參加記者會，於記者會由彭文君博士代表集團發表有關COVID-19檢測試劑、疫苗及治療藥物之近期開發進度。

UBI group

UBITh®設計型疫苗

廣譜新冠疫苗

精準設計型多重表為次單位疫苗UB-612

王長怡博士
more
聯亞生技四路並進攻堅新冠肺炎病毒帶來的災難
View More
UBI集團訊息
09122019
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」

聯合生物製藥(股)公司(聯生藥)今日宣布，其愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」
View More
UBI集團訊息
30112019
Mei Mei Hu — TIME 100 NEXT

Even with scientists as parents, it wasn’t always obvious that Mei Mei Hu would end up as the CEO of United Neuroscience, a company she co-founded in 2014 to find new ways to fight brain diseases like Alzheimer’s.

UBI group
more
Mei Mei Hu — TIME 100 NEXT
View More
UBI集團訊息
30112019
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421

The signing of a clinical trial agreement with NIH/NIAID for their sponsorship of a clinical trial with UB-421 for treatment of multi-drug resistant (MDR) HIV infection.

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
View More
UBI集團訊息
30112019
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議

NIH/NIAID將贊助UB-421應用於治療多重藥抗藥性(Multiple Drug Resistance，MDR)HIV感染之臨床試驗。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議
View More
UBI集團訊息
18112019
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria

They have received Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 1 clinical trial with a novel anti-IgE monoclonal antibody UB-221, in patients suffering from chronic spontaneous urticaria

UBI group

創新型IgE單株抗體UB-221
more
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
View More
UBI集團訊息
18112019
聯生藥單株抗體新藥 UB-221 獲美國 FDA 核准在慢性自發性蕁麻疹患者進行臨床一期試驗

新型抗IgE單株抗體藥物 UB-221 已獲得美國FDA 核准在標準一線藥物H1 抗組織胺治療無效的慢性自發性蕁麻疹病患進行臨床一期試驗

UBI group

創新型IgE單株抗體UB-221
more
聯生藥單株抗體新藥 UB-221 獲美國 FDA 核准在慢性自發性蕁麻疹患者進行臨床一期試驗
View More
UBI集團訊息
06102019
英國著名PharmaBoardRoom媒體記者、訪問聯生藥董事長暨科學長王長怡博士

王長怡乃UBI旗下子公司之一的聯合生物製藥（United BioPharma，UBP）董事長兼首席科學長，而UBP正是她所創立的UBI集團的其中一企業。

UBI group

王長怡博士
more
英國著名PharmaBoardRoom媒體記者、訪問聯生藥董事長暨科學長王長怡博士